JP2019523759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523759A5 JP2019523759A5 JP2018562123A JP2018562123A JP2019523759A5 JP 2019523759 A5 JP2019523759 A5 JP 2019523759A5 JP 2018562123 A JP2018562123 A JP 2018562123A JP 2018562123 A JP2018562123 A JP 2018562123A JP 2019523759 A5 JP2019523759 A5 JP 2019523759A5
- Authority
- JP
- Japan
- Prior art keywords
- pad4
- patient
- assay
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023008716A JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340560P | 2016-05-24 | 2016-05-24 | |
| US62/340,560 | 2016-05-24 | ||
| PCT/EP2017/062479 WO2017202879A1 (en) | 2016-05-24 | 2017-05-23 | Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008716A Division JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523759A JP2019523759A (ja) | 2019-08-29 |
| JP2019523759A5 true JP2019523759A5 (cg-RX-API-DMAC7.html) | 2020-07-02 |
| JP7217631B2 JP7217631B2 (ja) | 2023-02-03 |
Family
ID=59009670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562123A Active JP7217631B2 (ja) | 2016-05-24 | 2017-05-23 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
| JP2023008716A Ceased JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008716A Ceased JP2023058524A (ja) | 2016-05-24 | 2023-01-24 | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11613580B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3464358A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7217631B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017270027B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3024910A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA45112A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017202879A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11613580B2 (en) * | 2016-05-24 | 2023-03-28 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
| EP3924736A1 (en) * | 2019-02-15 | 2021-12-22 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing and assessing rheumatoid arthritis |
| US20210284744A1 (en) | 2020-03-15 | 2021-09-16 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| CN111458522B (zh) * | 2020-04-20 | 2024-01-09 | 杭州英邈生物科技有限公司 | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 |
| CN111733151B (zh) * | 2020-07-13 | 2021-11-12 | 山东新创生物科技有限公司 | 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| WO2004110244A2 (en) | 2003-05-08 | 2004-12-23 | Vanderbilt University | A gene equation to diagnose rheumatoid arthritis |
| EP1999152B1 (en) | 2006-03-27 | 2012-09-19 | Medimmune Limited | Binding member for gm-csf receptor |
| JP5252339B2 (ja) * | 2007-12-25 | 2013-07-31 | 地方独立行政法人東京都健康長寿医療センター | Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法 |
| ES2483724T3 (es) * | 2009-03-30 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarcadores, métodos y kits para el diagnóstico de artritis reumatoide |
| US20130101611A1 (en) * | 2009-11-25 | 2013-04-25 | The Johns Hopkins University | Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity |
| ES2660776T3 (es) | 2011-10-10 | 2018-03-26 | Medimmune Limited | Tratamiento para la artritis reumatoide |
| US8975033B2 (en) | 2012-11-05 | 2015-03-10 | The Johns Hopkins University | Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases |
| WO2015177097A1 (en) * | 2014-05-19 | 2015-11-26 | Medimmune Limited | Treatment for rheumatoid arthritis |
| US11613580B2 (en) * | 2016-05-24 | 2023-03-28 | Medimmune Limited | Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis |
-
2017
- 2017-05-23 US US16/304,055 patent/US11613580B2/en active Active
- 2017-05-23 MA MA045112A patent/MA45112A/fr unknown
- 2017-05-23 JP JP2018562123A patent/JP7217631B2/ja active Active
- 2017-05-23 CA CA3024910A patent/CA3024910A1/en active Pending
- 2017-05-23 WO PCT/EP2017/062479 patent/WO2017202879A1/en not_active Ceased
- 2017-05-23 EP EP17727829.8A patent/EP3464358A1/en active Pending
- 2017-05-23 AU AU2017270027A patent/AU2017270027B2/en active Active
-
2023
- 2023-01-24 JP JP2023008716A patent/JP2023058524A/ja not_active Ceased
- 2023-02-14 US US18/169,205 patent/US20230303707A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Papadopoulou et al. | Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care | |
| JP2019523759A5 (cg-RX-API-DMAC7.html) | ||
| JP6092625B2 (ja) | ＣＤ１９ｘＣＤ３二重特異性抗体を投与するための投与計画 | |
| Masuda et al. | Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder | |
| Shmais et al. | Proactive versus reactive therapeutic drug monitoring: why, when, and how? | |
| RU2013106938A (ru) | Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы | |
| JP2013527444A (ja) | 抗体を検出するための方法 | |
| Perry et al. | Vedolizumab dose escalation improves therapeutic response in a subset of patients with ulcerative colitis | |
| Sandborn et al. | Effects of transient and persistent anti-drug antibodies to certolizumab pegol: longitudinal data from a 7-year study in Crohn's disease | |
| WO2015034926A1 (en) | Treatment methods for rheumatoid arthritis | |
| JP2015530868A5 (cg-RX-API-DMAC7.html) | ||
| JP2023058524A (ja) | 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体 | |
| Vlam et al. | Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case–control study | |
| WO2016110595A1 (en) | A UNIVERSAL ASSAY FOR DETERMINING THE QUANTITY OF TNFα INHIBITORY DRUGS AND THEIR CORRESPONDING ANTI-DRUG-ANTIBODIES | |
| RU2016135417A (ru) | Новый анализ для детектирования периостина человека | |
| Uojima et al. | Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: a randomized study | |
| Finckh et al. | Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients | |
| Eric et al. | Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units | |
| JP2013511730A (ja) | 血小板バイオマーカーの正規化方法 | |
| Kim et al. | Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients | |
| Sammut et al. | Albuminuria in rheumatoid arthritis: associations with rheumatoid arthritis characteristics and subclinical atherosclerosis | |
| EP4558825A1 (en) | Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome | |
| Minawala et al. | Sarcopenia as a Preoperative Risk Stratification Tool among Older Adults with Inflammatory Bowel Disease | |
| CN103180731B (zh) | 纤维肌痛症的诊断剂、诊断方法及治疗剂 | |
| Qin et al. | The poor performance of cardiovascular risk scores in identifying patients with idiopathic inflammatory myopathies at high cardiovascular risk |